Upstream Bio (UPB) Competitors $18.56 +1.06 (+6.06%) Closing price 04:00 PM EasternExtended Trading$18.56 0.00 (0.00%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock UPB vs. MLTX, PTGX, HCM, APLS, INDV, MOR, KYMR, IMVT, CRNX, and XENEShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), HUTCHMED (HCM), Apellis Pharmaceuticals (APLS), Indivior (INDV), MorphoSys (MOR), Kymera Therapeutics (KYMR), Immunovant (IMVT), Crinetics Pharmaceuticals (CRNX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Upstream Bio vs. Its Competitors MoonLake Immunotherapeutics Protagonist Therapeutics HUTCHMED Apellis Pharmaceuticals Indivior MorphoSys Kymera Therapeutics Immunovant Crinetics Pharmaceuticals Xenon Pharmaceuticals Upstream Bio (NASDAQ:UPB) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment. Is UPB or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -3,836.58%. Upstream Bio's return on equity of -35.90% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Upstream Bio-3,836.58% -35.90% -26.26% MoonLake Immunotherapeutics N/A -40.98%-35.81% Do insiders and institutionals believe in UPB or MLTX? 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 13.6% of Upstream Bio shares are owned by company insiders. Comparatively, 12.1% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend UPB or MLTX? Upstream Bio presently has a consensus price target of $56.50, indicating a potential upside of 204.42%. MoonLake Immunotherapeutics has a consensus price target of $74.43, indicating a potential upside of 33.74%. Given Upstream Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Upstream Bio is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00MoonLake Immunotherapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the media refer more to UPB or MLTX? In the previous week, MoonLake Immunotherapeutics had 8 more articles in the media than Upstream Bio. MarketBeat recorded 17 mentions for MoonLake Immunotherapeutics and 9 mentions for Upstream Bio. MoonLake Immunotherapeutics' average media sentiment score of -0.06 beat Upstream Bio's score of -0.23 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation and earnings, UPB or MLTX? Upstream Bio has higher revenue and earnings than MoonLake Immunotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.37M422.18-$62.81MN/AN/AMoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-20.02 SummaryUpstream Bio beats MoonLake Immunotherapeutics on 7 of the 12 factors compared between the two stocks. Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.00B$3.09B$5.64B$9.82BDividend YieldN/A2.29%4.64%4.14%P/E RatioN/A20.6830.1125.77Price / Sales422.18329.08452.54168.61Price / CashN/A40.7837.7258.50Price / Book2.457.718.476.07Net Income-$62.81M-$54.65M$3.26B$265.11M7 Day Performance11.00%3.95%3.56%2.90%1 Month Performance61.67%11.46%5.97%4.00%1 Year PerformanceN/A13.04%42.70%26.92% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream Bio1.7738 of 5 stars$18.56+6.1%$56.50+204.4%N/A$1.00B$2.37M0.0038Earnings ReportMLTXMoonLake Immunotherapeutics2.2378 of 5 stars$53.06-0.5%$73.14+37.9%+21.1%$3.39BN/A-23.052PTGXProtagonist Therapeutics1.8977 of 5 stars$53.97+0.3%$66.10+22.5%+34.3%$3.34B$434.43M71.84120Earnings ReportAnalyst RevisionHCMHUTCHMED3.1809 of 5 stars$18.02+4.3%$28.00+55.4%-24.4%$3.14B$630.20M0.001,811Positive NewsAPLSApellis Pharmaceuticals4.6595 of 5 stars$24.54+1.2%$36.83+50.1%-33.9%$3.10B$781.37M-13.51770INDVIndivior1.5857 of 5 stars$21.35+0.6%$17.75-16.9%+84.4%$2.95B$1.17B34.521,051MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KYMRKymera Therapeutics3.2697 of 5 stars$43.44-0.5%$59.11+36.1%-6.2%$2.83B$47.07M-14.00170News CoveragePositive NewsEarnings ReportAnalyst RevisionIMVTImmunovant2.2659 of 5 stars$16.30+1.3%$36.40+123.3%-48.7%$2.79BN/A-5.95120Trending NewsEarnings ReportAnalyst ForecastCRNXCrinetics Pharmaceuticals3.4168 of 5 stars$29.24+3.6%$69.50+137.7%-42.5%$2.74B$1.04M-7.65210News CoverageEarnings ReportAnalyst ForecastXENEXenon Pharmaceuticals1.9797 of 5 stars$35.75+7.8%$54.82+53.3%-7.4%$2.73B$9.43M-11.03210Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies MLTX Alternatives PTGX Alternatives HCM Alternatives APLS Alternatives INDV Alternatives MOR Alternatives KYMR Alternatives IMVT Alternatives CRNX Alternatives XENE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPB) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access